Session » (0117–0144) Epidemiology & Public Health Poster I

Date: Sunday, November 12, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 0130

Association of HLA-DRB1 Alleles with Coronary Artery Calcium, Abdominal Aortic Calcium, and Carotid Intima-media Thickness in a Multi-ethnic Community-living Population

9:00AM-11:00AM: Abstract Number: 0135

Cancer Incidence and Risk Factors in Patients with Newly Diagnosed Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0143

Cancer Incidence in Familial Mediterranean Fever

9:00AM-11:00AM: Abstract Number: 0144

COVID-19 Infection in People with Immune Mediated Inflammatory Diseases Who Received SARSCo-V2 Vaccines

9:00AM-11:00AM: Abstract Number: 0133

COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Systemic Lupus Erythematosus: Results from the COVAD Study

9:00AM-11:00AM: Abstract Number: 0125

Decreasing Ischemic Heart Disease, but Increasing Cancer Among the Underlying Causes of Death in Decedents with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0122

Depression, Anxiety and Post-Traumatic Stress Disorder in Association with Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program

9:00AM-11:00AM: Abstract Number: 0126

Epidemiology and Retrospective Case-Control Analysis of IIM in the US Veteran Population

9:00AM-11:00AM: Abstract Number: 0140

Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database

9:00AM-11:00AM: Abstract Number: 0132

Feasibility of a Real-Time Risk Model to Identify Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease

9:00AM-11:00AM: Abstract Number: 0121

High Prevalence of Mental Health Disorders Among Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0131

Identifying Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease: Development and Validation of a Real-Time Risk Model

9:00AM-11:00AM: Abstract Number: 0123

Improving Interpretation of Work Outcomes in Patients with Inflammatory Rheumatic Musculoskeletal Disease: General Population Reference Curves for Work Ability and At-work Productivity

9:00AM-11:00AM: Abstract Number: 0141

In-patient Outcome Difference in Systemic Lupus Erythematous Patient Between Medicare and Non-Medicare Group, a Nationwide Analysis

9:00AM-11:00AM: Abstract Number: 0120

Incidence and Prevalence of Systemic Lupus Erythematosus in Urban China, 2013-2017: A Nationwide Population-based Study

9:00AM-11:00AM: Abstract Number: 0137

Incidence of and Risk Factors for Myelodysplastic Syndromes in Patients with Rheumatologic Diseases

9:00AM-11:00AM: Abstract Number: 0128

Incidence, Trends, and Determinants of Multimorbidity in Systemic Sclerosis: Data from a Population-based Cohort

9:00AM-11:00AM: Abstract Number: 0119

Mortality-related Health Metrics in Systemic Autoimmune Diseases: An Epidemiological Analysis of a Nationwide Register-based Cohort

9:00AM-11:00AM: Abstract Number: 0142

New-Onset Systemic Autoimmune Diseases Following COVID-19 Vaccination – Results from the COVAD Study

9:00AM-11:00AM: Abstract Number: 0118

Physical Performance Among Individuals with Systemic Lupus Erythematosus in a Diverse Population-Based Cohort

9:00AM-11:00AM: Abstract Number: 0138

Prevalence and Incidence of Sjögren’s Syndrome: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 0129

Rising Incidence and High Mortality of Systemic Sclerosis: A Population-based Cohort Study (2010-2020)

9:00AM-11:00AM: Abstract Number: 0134

Stressful Life Events in the Year Prior to Their Diagnosis Are Associated with Adult and Pediatric Systemic Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 0139

Systemic Vasculitides in Portugal and Brazil: Preliminary Results from the Reuma.pt/vasculitis Registry

9:00AM-11:00AM: Abstract Number: 0117

The Patient Journey to a First Diagnosis of Systemic Sclerosis: Temporal Disease Pattern Identification Using Machine Learning and Data Mining Among US and Japanese Patients

9:00AM-11:00AM: Abstract Number: 0136

The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-term Hydroxychloroquine Use

9:00AM-11:00AM: Abstract Number: 0127

Time Trends, Cumulative Incidence, and Impact on Survival of Interstitial Lung Disease in Systemic Sclerosis: Results from a Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 0124

Utility of the 2019 EULAR/ACR SLE Classification Criteria Score as Predictor for Mortality and Hospitalizations in a Population-Based Cohort: The Lupus Midwest Network

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].